Patent Application
20130203846
A phenyl carbamate compound; a composition for treating and/or preventing amyotrophic lateral sclerosis (ALS) containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or preventing ALS comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of ALS treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or preventing ALS, are provided.
Amyotrophic lateral sclerosis (ALS), which is also called as a Lou Gehrig disease, is accompanied by degeneration of both upper motor neurons (UMN) and lower motor neurons (LMN) and marked by neurogenic atrophy, weakness, and fasciculation. While the pathogenesis of ALS remains to be resolved, excitotoxicity has been expected to participate in the process of ALS. In particular, ALS patients show increased levels of extracellular glutamate and defects in glutamate transport. Administration of excitotoxins mimicked pathological changes in the spinal cord of ALS patients [Rothstein. Clin. Neurosci. 3:348-359 (1995); Ikonomidou, Qin, Labruyere, and Olney J. Neuropathol. Exp. Neurol. 55:211-224 (1996)].
UMN signs include hyperreflexia, extensor plantar response and weakness in a topographic representation. LMN signs include weakness, hyporeflexia, and fasciculations. Initial presentation varies. Affected individuals typically present with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Regardless of initial symptoms, atrophy and weakness eventually affect other muscles. The mean age of onset is 56 years in individuals with no known family history and 46 years in individuals with more than one affected family member (familial ALS or FALS). Average disease duration is about three years, but it can vary significantly. Death usually results from compromise of the respiratory muscles.
The diagnosis of ALS is based on clinical features, electrodiagnostic testing, and exclusion of other health conditions with related symptoms. Molecular genetic testing, available in clinical laboratories for several genes associated with ALS, plays a prominent role in diagnosis of the genetic subtype and genetic counseling.
Amyotrophic lateral sclerosis can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Genetic counseling and risk assessment depend on accurate determination of the specific genetic diagnosis.
Treatment is palliative. Individuals with ALS may benefit from care by a multidisciplinary team that includes a neurologist, specially trained nurses, pulmonologist, speech therapist, physical therapist, occupational therapist, respiratory therapist, nutritionist, psychologist, social worker, and genetics professional. Riluzole is the only currently FDA-approved drug for treatment of ALS. Oral secretions in those with bulbar symptoms can be reduced with tricylic antidepressants and other anticholinergic agents. Pseudobulbar affect can be managed with antidepressants. Swallowing difficulties can be alleviated by thickening liquids and pureeing solid food and, eventually, by use of a gastrostomy tube to help maintain caloric intake and hydration. Alphabet boards and computer-assisted devices can aid communication. Other assistive devices such as walkers, wheelchairs, bathroom modifications, hospital beds, and Hoyer lifts can aid in activities of daily life. Ventilatory assistance may include BIPAP and/or mechanical ventilation. Hospice care in terminal stages is beneficial.
ALS is a devastating paralyzing disorder, killing patients within three to five years after onset. Clinical symptoms primarily result from progressive degeneration of motoneurons in the spinal cord and brain stem, largely sparing cognitive performance. The disease affects healthy individuals in the midst of their life, sporadically in >90% of cases without any family history. Although more males than females are affected before the age of 60 years, both genders are similarly affected at an older age. With the ageing population, increasingly more individuals suffer ALS-the third most common neurodegenerative disorder.
Therefore, a need exists for a therapy that is effective in the treatment of ALS.
An embodiment provides an organic compound, i.e., phenyl carbamate compound. More particularly, the embodiment is directed to a phenyl carbamate compound of the following Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof:
wherein,
X is a halogen, for example, chlorine, fluorine, iodine, or bromine,
n, that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2,
R1 is a linear or branched alkyl group of C1-C4, for example, methyl group, ethyl group, isopropyl group, or butyl group,
A is hydrogen or a carbamoyl derivative represented by
B is hydrogen, a carbamoyl derivative represented by
trialkyl silyl groups (e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), or a trialkyl silyl ether group, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group,
A and B are not the carbamoyl derivative at same time, and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
The compound has remarkably excellent treatment and/or prevention effect on amyotrophic lateral sclerosis (ALS) as well as very low toxicity. Therefore, the compounds of formula I may be useful as a drug for the treatment and/or prevention of ALS.
Another embodiment provides a pharmaceutical composition for of preventing and/or treating amyotrophic lateral sclerosis (ALS) containing a compound of Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient
Another embodiment provides a method of preventing and/or treating ALS comprising administering a therapeutically effective amount of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of preventing and/or treating ALS.
Another embodiment provides a use of a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, in the prevention and/or treatment of ALS or in the manufacture of a medicament for preventing and/or treating ALS.
Continuing its research work in the field of ALS, the present inventors, as results of studies on the development of anti-ALS drugs, found that a phenyl carbamate compounds of the following Chemical Formula 1 exhibits remarkably excellent anti-ALS activity in various emulation models and simultaneously has very low toxicity, to complete the invention.
An embodiment provides an organic compound, particularly, a phenyl carbamate compound, more particularly, a phenyl carbamate compound represented by following Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof:
wherein,
X is a halogen, for example, chlorine, fluorine, iodine, or bromine,
n, that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2,
R1 is a linear or branched alkyl group of C1-C4, for example, methyl group, ethyl group, isopropyl group, or butyl group,
A is hydrogen or a carbamoyl derivative represented by
B is hydrogen, a carbamoyl derivative represented by
trialkyl silyl groups (e.g., a trimethyl silyl (TMS) group, a triethyl silyl (TES) group, a triisopropyl silyl (TIPS) group, t-butyl dimethyl silyl (TBDMS) group, and the like), trialkylaryl silyl groups (wherein the total number of alkyl and aryl groups is three; e.g., a t-butyl diphenyl silyl (TBDPS) group and the like), or a trialkyl silyl ether group, wherein each alkyl group may be independently selected from the group consisting of linear, branched, or cyclic C1-C4 alkyl groups, and each aryl group may be independently selected from the group consisting of C5-C8 aryl groups, preferably a phenyl group,
A and B are not the carbamoyl derivative at same time, and
R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.
In a concrete embodiment, the phenyl carbamate compound may be selected from the group consisting of:
In this compound, 2 chiral carbons exist at positions 1 and 2 from phenyl group substituted with X; thus, the compound may exist in the form of an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers, as well as a racemate.
Alternatively, the compound may be in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt may include an additional salt of acid or base, and its stereochemical isomer. For example, the compound may be in the form of an additional salt of an organic or inorganic acid. The salt may not be specially limited, and include any salts that maintain the activities of their parent compounds, with no undesirable effects, in the subject, when they are administered to the subject. Such salts may include inorganic and organic salts, such as salts of acetic acid, nitric acid, aspartic acid, sulfonic acid, sulfuric acid, maleic acid, glutamic acid, formic acid, succinic acid, phosphoric acid, phthalic acid, tannic acid, tartaric acid, hydrobromic acid, propionic acid, benzene sulfonic acid, benzoic acid, stearic acid, lactic acid, bicarbonic acid, bisulfuric acid, bitartaric acid, oxalic acid, butyric acid, calcium edetate, carbonic acid, chlorobezoic acid, citric acid, edetic acid, toluenesulfonic acid, fumaric acid, gluceptic acid, esilic acid, pamoic acid, gluconic acid, methyl nitric acid, malonic acid, hydrochloric acid, hydroiodic, hydroxynaphtholic acid, isethionic acid, lactobionic acid, mandelic acid, mucic acid, naphthylic acid, muconic acid, p-nitromethanesulfonic acid, hexamic acid, pantothenic acid, monohydrogen phosphoric acid, dihydrogen phosphoric acid, salicylic acid, sulfamic acid, sulfanilic acid, methane sulfonic acid, and the like. The additional salts of base may include salts of akali metal or alkaline earth metal, such as salts of ammonium, lithium, sodium, potassium, magnesium, calcium, and the like; salts having an organic base, such as benzathine, N-methyl-D-glucamine, hydrabamine, and the like; and salts having an amino acid such as arginine, lysine, and the like. In addition, these salts may be converted to a released form by treating with a proper base or acid.
As demonstrated in the following experimental examples, the compound of Chemical Formula 1, a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or pharmaceutically acceptable salt thereof exhibits an excellent effect on preventing and/or treating ALS.
Therefore, another embodiment provides a pharmaceutical composition for preventing and/or treating ALS containing a phenyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.
Another embodiment provides a method of preventing and/or treating ALS comprising administering a therapeutically effective amount of a phenyl alkyl carbamate compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of preventing and/or treating ALS. The method may further comprise a step of identifying the subject in need of preventing and/or treating ALS prior to the step of administering. The term “therapeutically effective amount” may refer to an amount of the active gradient capable of exhibiting the effect of preventing and/or treating ALS.
Another embodiment provides a phenyl carbamate compound represented by Chemical Formula 1, a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of ALS or in the manufacture of a medicament for preventing and/or treating ALS. Another embodiment provides a use of a phenyl carbamate compound represented by Chemical Formula 1, a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt thereof, in the prevention and/or treatment of ALS or in the manufacture of a medicament for preventing and/or treating ALS.
Amyotrophic lateral sclerosis (ALS) is involving both upper motor neurons (UMNs) and lower motor neurons (LMNs). Upper motor neurons, located in the motor cortex of the frontal lobe, send their axons through the great corticofugal tracts to the brain stem (corticobulbar neurons) and the spinal cord (corticospinal neurons) to influence patterned activity of the lower motor neurons (LMS). Additional UMN influences on the LMN are carried over descending pathways of the brain stem. UMN signs in ALS include hyperreflexia and extensor plantar response. Lower motor neurons, located in the brain stem and spinal cord, innervate striated muscle. LMN signs in ALS include weakness, muscle wasting (atrophy), hyporeflexia and fasciculations.
Symptoms present in early disease may vary. Affected individuals most often present with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Other findings may include lability of affect, but not necessarily mood. A diagnostic feature of ALS, typically not seen in other disorders, is the presence of hyperreflexia in segmental regions of muscle atrophy, unaccompanied by sensory disturbance.
Limb involvement occurs more often than bulbar involvement. Onset in the lower extremities is most common for familial ALS [Mulder et al 1986, Siddique 1991]. Various subtypes of ALS may be identified:
Regardless of initial symptoms, atrophy and weakness eventually spread to affect other muscles.
Oculomotor neurons are generally resistant to degeneration in ALS, but may be affected in individuals with a long disease course, especially when life span is extended by ventilatory support. Once all muscles of communication and expression are paralyzed, the individual is “locked in.” In some instances, eye movements remain intact, allowing communication by way of special devices. Death usually results from compromise of the respiratory muscles.
In a concrete embodiment, the ALS may include a neurodegeneration associated ALS, and in another embodiment, the ALS may not be a muscle spasm associated ALS.
The pharmaceutical composition may be formulated in various forms for oral or parenteral administration. For example, the pharmaceutical composition may be formulated in the oral administration form, such as a tablet, pill, soft or hard capsule, liquid, suspension, emulsion, syrup, granules, elixirs, and the like. In addition to the active ingredient, the oral administration form may further include pharmaceutically acceptable and conventional components, for example, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, and the like; a lubricant such as silica, talc, stearic acid, magnesium or calcium salt thereof, polyethyleneglycol, and the like.
In the case that the oral administration form is a tablet, it may further include a binder such as magnesium aluminium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpirrolidine, and the like; and optionally include one or more additives selected from the group consisting of a disintegrant such as starch, agar, arginic acid or sodium salt thereof, an absorbent, a colorant, a flavoring, a sweetener, and the like.
Alternatively, the pharmaceutical composition may also be formulated in a parenteral administration form, which can be administered by subcutaneous injection, intravenous injection, intramuscular injection, injection into thoracic cavity, and the like. In order to formulate the parenteral administration form, the pharmaceutical composition may be prepared as a solution or suspension wherein the active ingredient is dissolved in water together with a stabilizer and/or a buffering agent, and such solution or suspension formulation may be prepared as a dosage form in ample or vial.
The pharmaceutical composition may be sterilized, and/or include further additives such as a preservative, a stabilizer, a hydrating agent, an emulsification accelerator, a salt and/or buffering agent for osmoregulation, and the like, and/or further therapeutically effective ingredients. The pharmaceutical composition may be formulated by any conventional method for mixing, granulating, coating, and the like.
The pharmaceutical composition may be administered to a mammal including human, in the therapeutically effective amount of 0.01 to 750 mg/kg (body weight), preferably 0.1 to 500 mg/kg (body weight) per one day, based on the active ingredient. The therapeutically effective amount may be administered through oral or parenteral pathway, one or two or more times per one day.
The therapeutically effective amount and the administration pathway of the present pharmaceutical composition may be properly adjusted by a person skilled in the relevant field considering the conditions of the subject (patient), desired effects, and the like.
The subject may be a mammal including human or cells and/or tissues separated therefrom.
The phenyl carbamate compound of the present invention may prepared by the following reaction formula.
A diol compound used in the synthesis of the carbamate compound may be synthesized by dihydroxylation of a trans-olefin compound. A diol compound having optical activity may be synthesized using a sharpless asymmetric dihydroxylation catalyst.
As indicated in the Reaction Formula II, the optically active substance of diol may also be synthesized using a reduction reagent after synthesizing a hydroxy-ketone compound using Haloro-Mandelic acid. In the Reaction Formula II, PG may be Trialkyl Silyl group (TMS, TES, TIPS, TBDMS, TBDPS), Ether group [BOM(Benzyloxymethyl ether). MTM(Methylthiomethyl ether), SEM(2-(Trimethylsilyl)ethoxymethyl ether), PMBM(p-Methoxybenzyl ether), THP(Tetrahydropyranyl ether), Allyl ether, Trityl ether, Ester group [Ac(acetate), Bz(Benzoate), Pv(Pivaloate), Cbz(Benzyl carbonate), BOC(t-Butyl carbonate), Fmoc(9-Fulorenylmethyl)carbonate, Alloc(Allyl Carbonate), Troc(Trichloroethyl carbonate), or p-Methoxybenzoate, Methyl carbonate, and so on.
As a highly selectivity form of regioisomer of single carbamate of diol having halogen substituent at phenyl ring. (Example 1˜14 and 36˜67 are synthesized by reaction formula III)
Two substances in the form of regioisomers of a single carbamate of diol having halogen substituent at phenyl ring may be separated by flash column chromatography to obtain two kinds of single carbamate compounds. (Example 15˜35 and 68˜115 are synthesized by reaction formula IV)
In the Reaction Formula V, PG may be Trialkyl Silyl group (TMS, TES, TIPS, TBDMS, TBDPS), Ether group [BOM(Benzyloxymethyl ether). MTM(Methylthiomethyl ether), SEM(2-(Trimethylsilyl)ethoxymethyl ether), PMBM(p-Methoxybenzyl ether), THP(Tetrahydropyranyl ether), Allyl ether, Trityl ether, Ester group [Ac(acetate), Bz(Benzoate), Pv(Pivaloate), Cbz(Benzyl carbonate), BOC(t-Butyl carbonate), Fmoc(9-Fulorenylmethyl)carbonate, Alloc(Allyl Carbonate), Troc(Trichloroethyl carbonate), or p-Methoxybenzoate, Methyl carbonate, and so on.
The present invention is further explained in more detail with reference to the following examples. These examples, however, should not be interpreted as limiting the scope of the present invention in any manner.
48 ml of 2-chlorobenzenaldehyde (0.42 mol) and 49.7 ml of 3-pentanone (0.47 mol) were dissolved in 600 mL of hexane in flask, and then stirred with raising the temperature. 53.6 ml of Boron trifluoride etherate (BF3OEt2, 0.42 mol) was added to the resultant under reflux conditions. When the reaction was completed, water was added thereto. After layer separation, the obtained organic layer was washed twice with 1M sodium hydroxide solution (1M NaOH), and then the separated organic layer was washed with water. The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4) and concentrated. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (38 g, yield 58%). 1H NMR (400 MHz, CDCl3) δ1.94 (d, J=4.8 Hz, 3H), 6.24 (m, 1H), 6.78 (d, J=14 Hz, 1H), 7.11˜7.51 (m, 4H)
The substantially same method as described in Preparation Example 1 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (2.9 g, yield 83%).
1H NMR (400 MHz, CDCl3) δ1.14 (d, J=7.6 Hz, 3H), 2.29˜2.33 (m, 2H), 6.28 (dt, J=16 Hz, 6.4 Hz, 1H), 6.78 (d, J=15.6 Hz, 1H), 7.13˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (8.0 g, yield 50˜90%).
1H NMR (400 MHz, CDCl3) δ1.14 (d, J=6.8 Hz, 6H), 2.25˜2.57 (m, 1H), 6.20 (dd, J=16 Hz, 7.2 Hz, 1H), 7.64 (d, J=16 Hz, 1H), 7.12˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 1 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (10 g, yield 85%).
1H NMR (400 MHz, CDCl3) δ0.96 (1, J=7.2 Hz, 3H), 1.33˜1.56 (m, 4H), 2.26˜2.32 (m, 4H), 6.24 (dt, J=15.6 Hz, 7 Hz, 1H), 6.78 (d, J=16 Hz, 1H), 7.13˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 1 was conducted, except that 2,4-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (2.4 g, yield 57%).
1H NMR (400 MHz, CDCl3) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.24 (m, 1H), 6.72 (d, J=15.6 Hz, 1H), 7.18˜7.44 (m, 3H)
The substantially same method as described in Preparation Example 5 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (2.1 g, yield 90%).
1H NMR (400 MHz, CDCl3) δ1.14 (d, J=7.6 Hz, 3H), 2.20˜2.33 (m, 2H), 6.26 (dt, J=16 Hz, 6.8 Hz, 1H), 6.70 (d, J=15.6 Hz, 1H), 7.18˜7.46 (m, 3H)
The substantially same method as described in Preparation Example 5 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (0.23 g, yield 10˜40%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.8 Hz, 6H), 2.53˜2.58 (m, 1H), 6.19 (dd, J=16.4 Hz, 6.8 Hz, 1H), 6.31 (d, J=16.4 Hz, 1H), 7.18˜7.46 (m, 3H)
The substantially same method as described in Preparation Example 5 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (3.2 g, yield 40˜80%).
1H NMR (400 MHz, CDCl3) δ0.96 (t, J=7.2 Hz, 3H), 1.38˜1.52 (m, 4H), 2.25˜2.31 (m, 2H), 6.22 (dt, J=15.6 Hz, 6.8 Hz, 1H), 6.70 (d, J=15.6 Hz, 1H), 7.18˜7.46 (m, 3H)
The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.4 g, yield 10˜40%).
1H NMR (400 MHz, CDCl3) δ1.98 (d, J=8 Hz, 3H), 6.23˜6.31 (m, 1H), 6.40 (d, J=16 Hz, 1H), 7.05˜7.32 (m, 3H)
The substantially same method as described in Preparation Example 9 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (1.2 g, yield 10˜40%).
1H NMR (400 MHz, CDCl3) δ1.17 (t, J=7.6 Hz, 3H), 2.30˜2.37 (m, 2H), 6.29 (dt, J=16.4 Hz, 6 Hz, 1H), 6.37 (d, J=16.4 Hz, 1H), 7.05˜7.32 (m, 3H)
The substantially same method as described in Preparation Example 9 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (0.23 g, yield 10˜40%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.8 Hz, 6H), 2.53˜2.58 (m, 1H), 6.19 (dd, J=16.4 Hz, 6.8 Hz, 1H), 6.31 (d, J=16.4 Hz, 1H), 7.05˜7.32 (m, 3H)
The substantially same method as described in Preparation Example 9 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (0.2 g, yield 10˜40%).
1H NMR (400 MHz, CDCl3) δ0.99 (t, J=7.2 Hz, 3H), 1.14˜1.59 (m, 4H), 2.30˜2.36 (m, 2H), 6.24 (dt, J=16 Hz, 6.6 Hz, 1H), 6.38 (d, J=16.4 Hz, 1H), 7.05˜7.33 (m, 3H)
The substantially same method as described in Preparation Example 1 was conducted, except that 2,3-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.2 g, yield 10˜40%).
1H NMR (400 MHz, CDCl3) δ1.94 (d, J=4.8 Hz, 3H), 6.24 (m, 1H), 6.78 (d, J=14 Hz, 1H), 7.11˜7.51 (m, 3H)
1-(2-chlorophenyl)-trans-1-propene (1.5 g, Preparation Example 1) was dissolved in 30 mL of the mixture of t-BuOH/H2O (1:1 (V/V)). At 0° C., AD-mix-α (Aldrich, U.S.A.) (13.7 g) and methane sulfone amide (CH3SO2NH2, 0.76 g, 0.0080 mol) were added thereto and stirred for overnight. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na2SO3) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (1.65 g, yield 90%).
1H NMR (400 MHz, CDCl3) δ1.20 (d, J=6.4 Hz, 3H), 2.48 (d, J=4.0 Hz 1H), 2.92 (d, J=4.4 Hz, 1H), 3.93˜3.97 (m, 1H), 4.97 (t, J=4.8 Hz, 1H), 7.22˜7.51 (m, 4H)
13CNMR (100 MHz, CDCl3) δ18.8, 71.5, 74.4, 127.1, 128.1, 128.9, 129.5, 132.6, 138.9
1-(2-chlorophenyl)-trans-1-propene (2.5 g, Preparation Example 1) was dissolved in 50 mL of the mixture of t-BuOH/H2O (1:1 (V/V)). At 0° C., AD-mix-α (Aldrich, U.S.A.) (23.5 g) and methane sulfone amide (CH3SO2NH2, 1.27 g, 0.013 mol) were added thereto and stirred for overnight. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na2SO3) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (2.96 g, yield 90%).
1H NMR (400 MHz, CDCl3) δ1.20 (d, J=6.4 Hz, 3H), 2.48 (d, J=4.0 Hz, 1H), 2.92 (d, J=4.4 Hz, 1H), 3.93˜3.97 (m, 1H), 4.97 (t, J=4.8 Hz, 1H), 7.22˜7.51 (m, 4H)
1-(2-chlorophenyl)-trans-1-propene (6.53 g, Preparation Example 1) was dissolved in 45 mL of the mixture of acetone/t-BuOH/H2O (5:1:1 V/V). At the room temperature, N-methylmorpholine-N-oxide (7.51 g) and OsO4 (0.54 g) were added thereto and stirred for 2-3 hours. When the reaction was completed, the obtained product was washed with water and methylenechloride (MC). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (6.42 g, yield 80%).
1H NMR (400 MHz, CDCl3) δ1.20 (d, J=6.4 Hz, 3H), 2.48 (d, J=4.0 Hz, 1H), 2.92 (d, J=4.4 Hz, 1H), 3.93˜3.97 (m, 1H), 4.97 (t, J=4.8 Hz, 1H), 7.22˜7.51 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-chlorophenyl)-trans-1-butene (Preparation Example 2) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.36 g, yield 95%).
1H NMR (400 MHz, CDCl3) δ1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-chlorophenyl)-trans-1-butene (Preparation Example 2) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.84 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2-chlorophenyl)-trans-1-butene (Preparation Example 2) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (5.1 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.01 (1, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-chlorophenyl)-3-methyl-trans-1-butene (Preparation Example 3) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.96 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.07 (1, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-chlorophenyl)-3-methyl-trans-1-butene (Preparation Example 3) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (4.2 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.07 (1, J=7.2 Hz, 6H), 1.82˜1.90 (m, 1H), 1.93 (d, J=5.6 Hz, 1H), 2.79 (d, J=6 Hz, 1H), 3.53˜3.57 (m, 1H), 5.23˜5.25 (m, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2-chlorophenyl)-3-methyl-trans-1-butene (Preparation Example 3) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.8 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.07 (1, J=7.2 Hz, 6H), 1.83˜1.90 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-chlorophenyl)-trans-1-hexene (Preparation Example 4) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.37 g, yield 90%).
1H NMR (400 MHz, CDCl3) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.23˜7.53 (m, 4H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-chlorophenyl)-trans-1-hexene (Preparation Example 4) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (4.2 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.91 (t, J=6.6 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.8 Hz, 1H), 2.70 (d, J=5.2 Hz, 1H), 3.80˜3.83 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.24˜7.56 (m, 4H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2-chlorophenyl)-trans-1-hexene (Preparation Example 4) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (7.9 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.90 (t, J=7.2 Hz, 3H), 1.26˜1.55 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.6 Hz, 1H), 3.78˜3.84 (m, 1H), 5.04 (t, J=3.2 Hz, 1H), 7.24˜7.55 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 5) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.33 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.22 (d, J=6.4 Hz, 3H), 2.10 (d, J=4.4 Hz, 1H), 2.71 (d, J=4.8 Hz, 1H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.40 (d, J=2.0 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 5) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.45 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.22 (d, J=6.4 Hz, 3H), 2.10 (d, J=4.4 Hz, 1H), 2.71 (d, J=4.8 Hz, 1H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 5) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.45 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.22 (d, J=6.4 Hz, 3H), 2.10 (d, J=4.4 Hz, 1H), 2.71 (d, J=4.8 Hz, 1H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-butene (Preparation Example 6) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.32 g, yield 90%).
1H NMR (400 MHz, CDCl3) δ1.02 (1, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 2.07 (d, J=4.8 Hz, 1H), 2.74 (d, J=4.8 Hz, 1H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-butene (Preparation Example 6) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.43 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.02 (1, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 2.07 (d, J=4.8 Hz, 1H), 2.74 (d, J=4.8 Hz, 1H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-butene (Preparation Example 6) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.33 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.02 (1, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 2.07 (d, J=4.8 Hz, 1H), 2.74 (d, J=4.8 Hz, 1H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 77.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 7) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.25 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 7) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.36 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 7) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.26 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-hexene (Preparation Example 8) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.1 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 2.05 (d, J=5.2 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 8) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.2 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 2.05 (d, J=5.2 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 8) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.67 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 2.05 (d, J=5.2 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-propene (Preparation Example 9) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.9 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-propene (Preparation Example 9) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.84 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-propene (Preparation Example 9) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.91 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-butene (Preparation Example 10) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.23 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 2.64 (dd, J=0.8 Hz, J=4.0 Hz, 1H), 3.14 (d, J=8.4 Hz, 1H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-butene (Preparation Example 10) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.96 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 2.64 (dd, J=0.8 Hz, J=4.0 Hz, 1H), 3.14 (d, J=8.4 Hz, 1H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-butene (Preparation Example 10) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.86 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 2.64 (dd, J=0.8 Hz, J=4.0 Hz, 1H), 3.14 (d, J=8.4 Hz, 1H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 11) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.25 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 11) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.37 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 11) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.47 g, yield 60˜95%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-hexene (Preparation Example 12) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.36 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=6.8 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 2.61˜2.62 (m, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-hexene (Preparation Example 12) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.58 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=6.8 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 2.61˜2.62 (m, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-hexene (Preparation Example 12) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.62 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=6.8 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 2.61˜2.62 (m, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)
15 g of (R)-2-chloromandelic acid was mixed with methanol (CH3OH, 150 ml) and phosphorus chloride oxide (POCl3, 0.76 ml) in a flask by stiffing using a magnetic stirrer at the room temperature for 6 hours. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na2SO3) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (15.64 g, yield 95%).
1H NMR (400 MHz, CDCl3) δ 3.59 (d, J=5.2, 1H), 3.79 (t, J=6.0, 3H), 5.59 (d, J=5.2, 1H), 7.28˜7.43 (m, 4H)
N,O-dimethylhydroxylamine hydrochloride (N,O-dimethylhydroxylamine.HCl, 15.2 g) was dissolved in dichloromethane (DCM, 150 ml), and cooled to 0° C. using an ice-bath. Then, 77.7 ml of 2.0M trimethylaluminium in hexane was slowly added thereto in drop-wise manner for 30 minutes. Thereafter, the ice-bath was removed, and the obtained product was stirred at the room temperature for 2 hours. Methyl-2-(2-chlorophenyl)-(R)-2-hydroxyacetate (15.64 g) dissolved in dichloromethane (DCM, 150 ml) was added in drop-wise manner thereto at the room temperature for 30 minutes, and subjected to reflux for 12 hours. When the reaction was completed, the obtained product was cooled to 0° C., and washed by a slow drop-wise addition of hydrochloric acid (HCl, 200 ml). The obtained organic layer was washed with distilled water and brine, dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (14.68 g, yield 82%).
1H NMR (400 MHz, CDCl3) δ3.23 (s, 3H), 3.28 (s, 3H), 4.33 (d, J=6.0 Hz, 1H), 5.81 (d, J=5.6 Hz, 1H), 7.23˜7.42 (m, 4H)
2-(2-chlorophenyl)-(R)-2-hydroxy-N-methoxy-N-methylacetamide (0.81 g, 3.52 mmol) obtained in Preparation Example 51 was dissolved in dichloromethane (DCM), and cooled to 0° C. Imedazole (0.36 g, 5.28 mmol) was slowly added, and stirred. TBDMS-Cl (t-butyldimethylsily chloride, 0.79 g, 5.28 mmol) was slowly added. When the reaction was completed, the reaction mixture was quenched with H2O. The organic layer was separated and collected. The aqueous layer was extracted with CH2Cl2 (300 mL), dried over MgSO4. Concentration under vacuum provided a title compound. (0.97 g, 80˜95%).
1H NMR (400 MHz, CDCl3) δ−0.03 (s, 3H), 0.14 (s, 3H), 0.94 (s, 9H), 2.97 (s, 3H), 3.02 (s, 3H), 5.83 (s, 1H), 7.25˜7.60 (m, 4H)
2-(2-chlorophenyl)-N-methoxy-(R)-2-(t-butyldimethylsiloxy)-N-methylacetamide (0.9 g) obtained in Preparation Example 52 was dissolved in tetrahydrofuran (THF), and cooled to 0° C. 3.0M methyl magnesium bromide (MeMgBr, 2.18 ml) solution in ether was added thereto in drop-wise manner for 30 minutes, and the obtained product was stirred at 0° C. When the reaction was completed, diethylether was added thereto. The obtained product was washed with 10% (w/v) potassium hydrogen sulfate (KHSO4, 100 ml) and then, washed again with brine. The obtained organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concentrated under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (0.69 g, yield 85˜95%).
1H NMR (400 MHz, CDCl3) δ−0.3 (s, 3H), 0.14 (s, 3H), 0.94 (s, 9H), 2.18 (s, 3H), 5.50 (s, 1H), 7.27˜7.56 (m, 4H)
1-(2-chlorophenyl)-(R)-1-(t-butyldimethyl-siloxy)propane-2-on (0.14 g) obtained in Preparation Example 53 was dissolved in ether, and cooled to −78° C. Zinc borohydride (Zn(BH4)2) was slowly added thereto and the obtained product was stirred. When the reaction was completed, the obtained product was washed by H2O. The obtained organic layer was washed with H2O, dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concentrated under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (0.04 g, yield 25˜33%, cis:trans=2:1).
1H NMR (400 MHz, CDCl3) δ−0.11 (s, 3H), 0.11 (s, 3H), 0.93 (S, 9H), 1.07 (d, J=6.4 3H), 2.05 (d, J=6.4 1H), 4.01˜4.05 (m, 1H), 5.18 (d, J=4.0, 1H), 7.20˜7.56 (m, 4H))
1-(2-chlorophenyl)-(R)-1-(t-butyldimethyl-siloxy)-(S)-2-propanol (10.38 g) obtained in Preparation Example 54 was dissolved in methanol (CH3OH, 100 ml), and then, cooled to 0° C. 8M hydrochloric acid (HCl, 56.2 ml) was slowly added in drop-wise manner to the obtained product, and then, the obtained product was warmed to the room temperature, and stirred for 15 hours. When the reaction was completed, the obtained product was cooled to 0° C. 5N sodium hydroxide (NaOH, 30 ml) was slowly added thereto, and the obtained product was subjected to vacuum concentration. The obtained product was diluted with ethylacetate. The obtained organic layer was washed with distilled water, dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (7.05 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.07 (d, J=6.8, 3H), 2.01 (d, J=5.6, 1H), 2.61 (s, 1H), 4.21˜4.27 (m, 1H), 5.24 (d, J=3.6, 1H), 7.22˜7.64 (m, 4H)
The substantially same method as described in Preparation Example 50˜55 was conducted, except that (S)-2-chloromandelic acid was used instead of (R)-2-chloromandelic acid, to obtain the title compound (5.04 g, yield 84%).
1H NMR (400 MHz, CDCl3) δ1.07 (d, J=6.8, 3H), 2.00 (d, J=5.6, 1H), 2.54 (d, J=3.6, 1H), 4.22˜4.26 (m, 1H), 5.25 (t, J=3.2, 1H), 7.22˜7.65 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,3-dichlorophenyl)-trans-1-propene (Preparation Example 13) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.9 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜ (m, 3H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,3-dichlorophenyl)-trans-1-propene (Preparation Example 13) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.84 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜ (m, 3H)
The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,3-dichlorophenyl)-trans-1-propene (Preparation Example 13) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.91 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜ (m, 3H)
The substantially same method as described in Preparation Example 1 was conducted, except that 2-fluorobenzenaldehyde was used instead of 2-chlorobenzenealdehyde, to obtain the title compound (6.67 g, yield 61%).
1H NMR (400 MHz, CDCl3) δ1.94 (d, J=6.8 Hz, 3H), 6.30˜6.38 (m, 1H), 6.57 (d, J=16 Hz, 1H), 7.00˜7.41 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-fluorophenyl)-trans-1-propene (Preparation Example 60) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (6.46 g, yield 78%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 2.43 (d, J=3.6 Hz, 1H), 2.69 (d, J=4.8 Hz, 1H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 7.04˜7.50 (m, 4H)
The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-fluorophenyl)-trans-1-propene (Preparation Example 60) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (3.29 g, yield 79%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 2.43 (d, J=3.6 Hz, 1H), 2.69 (d, J=4.8 Hz, 1H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 7.04˜7.50 (m, 4H)
In a flask, 2-iodobenzyl alcohol (4 g, 17.09 mmol) was dissolved in dichloromethane (MC, 85 ml), and then, manganese oxide (MnO2, 14.86 g, 170.92 mmol) was added thereto. The obtained reaction product was stirred under the reflux condition. When the reaction was completed, the obtained reaction product was cooled to the room temperature, and then, fiteated and concentrated using celite, to obtain the title compound (3.6 g, yield 91%).
1H NMR (400 MHz, CDCl3) δ7.30˜7.99 (m, 4H), 10.10 (s, 1H)
The substantially same method as described in Preparation Example 1 was conducted, except that 2-iodobenzenealdehyde (Preparation Example 63) was used instead of 2-chlorobenzenealdehyde, to obtain the title compound (3.4 g, yield 65%).
1H NMR (400 MHz, CDCl3) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.09˜6.18 (m, 1H), 6.60 (dd, J=15.66 Hz, 1.8 Hz, 1H), 6.89˜7.84 (m, 4H)
The substantially same method as described in Preparation Example 64 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (8.5 g, yield 75%).
1H NMR (400 MHz, CDCl3) δ1.46 (t, J=7.6 Hz, 3H), 2.26˜2.34 (m, 2H), 6.17 (dt, J=15.6 Hz, 6.6 Hz 1H), 6.57 (d, J=15.6 Hz, 1H), 6.89˜7.85 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (3.4 g, yield 88%).
1H NMR (400 MHz, CDCl3) δ1.27 (d, J=6.4 Hz, 3H), 2.26 (br s, 1H), 2.74 (br s, 1H), 3.99 (t, J=6.0 Hz, 1H), 4.81 (d, J=4.0 Hz, 1H), 7.01˜7.87 (m, 4H)
The substantially same method as described in Preparation Example 15 was conducted was conducted, except that 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (7.4 g, yield 84%).
1H NMR (400 MHz, CDCl3) δ1.26 (d, J=6.4 Hz, 3H), 2.35 (br s, 1H), 2.85 (br d, J=4.0 Hz, 1H), 3.98 (t, J=6.2 Hz, 1H), 4.80 (dd, J=5.0, 4.4 Hz, 1H), 7.00˜7.87 (m, 4H)
The substantially same method as described in Preparation Example 14 was conducted was conducted, except that 1-(2-iodophenyl)-trans-1-butene (Preparation Example 65) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (9.5 g, yield 84%).
1H NMR (400 MHz, CDCl3) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 7.01˜7.87 (m, 4H)
To a stirred solution of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14, 67 g, 0.35 mol) in CH2Cl2 (670 ml) was added Et3N (200 mL, 1.43 mol) and TMSCl (113.9 mL, 0.89 mol) at 0° C. under N2. The reaction mixture was allowed to stir at 0° C. for 3 hr. The reaction mixture was quenched with H2O (650 mL) at 0° C. The organic layer was separated and collected. The aqueous layer was extracted with CH2Cl2 (300 mL), dried over MgSO4 Concentration under vacuum provided a crude product. 104.18 g (117.44%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=5.6 Hz, 3H), 3.977˜3.918 (m, 1H), 4.973 (d, J=6.4 Hz, 1H), 7.207˜7.165 (m, 1H), 7.321˜7.245 (m, 2H), 7.566˜7.543 (m, 1H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-propanediol (Preparation example 15) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (8.5 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=5.6 Hz, 3H), 3.977˜3.918 (m, 1H), 4.973 (d, J=6.4 Hz, 1H), 7.21˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)propane-1,2-diol (Preparation example 16) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (5.2 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=5.6 Hz, 3H), 3.977˜3.918 (m, 1H), 4.973 (d, J=6.4 Hz, 1H), 7.21˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(S,R)-1,2-propanediol (Preparation example 56) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.4 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=5.6 Hz, 3H), 3.977˜3.918 (m, 1H), 4.973 (d, J=6.4 Hz, 1H), 7.21˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(R,S)-1,2-propanediol (Preparation example 55) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.2 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=5.6 Hz, 3H), 3.977˜3.918 (m, 1H), 4.973 (d, J=6.4 Hz, 1H), 7.21˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(S,S)-1,2-butanediol (Preparation example 17) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-butanediol (Preparation example 18) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.5 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-1,2-butanediol (Preparation example 19) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.0 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 20) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title (2.7 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-3-methyl-(R,R)-1,2-butanediol (Preparation example 21) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.4 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-3-methyl-1,2-butanediol (Preparation example 22) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.8 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(S,S)-1,2-hexanediol (Preparation example 23) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.1 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.23˜7.53 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-hexanediol (Preparation example 24) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.3 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.23˜7.53 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-chlorophenyl)-1,2-hexanediol (Preparation example 25) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.2 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.23˜7.53 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-propanediol (Preparation example 26) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.4 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.22 (d, J=6.4 Hz, 3H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.40 (d, J=2.0 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-propanediol (Preparation example 38) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.4 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.10 (d, J=6.4 Hz, 3H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.13˜7.36 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,3-dichlorophenyl)-(S,S)-1,2-propanediol (Preparation example 57) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.2 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.10 (d, J=6.4 Hz, 3H,), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.22 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-butanediol (Preparation example 29) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.1 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.02 (t, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-butanediol (Preparation example 41) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.8 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 32) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.7 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.30˜7.53 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 44) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.3 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-hexanediol (Preparation example 90) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.6 (m, 2H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-hexanediol (Preparation example 47) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.8 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.85 (t, J=6.7 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-propanediol (Preparation example 27) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.2 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.22 (d, J=6.4 Hz, 3H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-propanediol (Preparation example 39) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.10 (d, J=6.4 Hz, 3H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,3-dichlorophenyl)-(R,R)-1,2-propanediol (Preparation example 58) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.9 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.10 (d, J=6.4 Hz, 3H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.22 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-butanediol (Preparation example 30) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.02 (t, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-butanediol (Preparation example 42) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.3 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol (Preparation example 33) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.5 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.30˜7.53 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol (Preparation example 45) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.4 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-hexanediol (Preparation example 36) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-hexanediol (Preparation example 48) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.3 g, yield 90˜120%)
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.85 (t, J=6.7 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-propanediol (Preparation example 28) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.22 (d, J=6.4 Hz, 3H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-propanediol (Preparation example 40) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.1 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.10 (d, J=6.4 Hz, 3H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,3-dichlorophenyl)-1,2-propanediol (Preparation example 59) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.7 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.10 (d, J=6.4 Hz, 3H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.22 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-butanediol (Preparation example 31) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.9 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.02 (t, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-butanediol (Preparation example 43) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.1 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-1,2-butanediol (Preparation example 34) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.7 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.30˜7.53 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-1,2-butanediol (Preparation example 46) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.6 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-hexanediol (Preparation example 37) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.7 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-hexanediol (Preparation example 49) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.2 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 0.85 (t, J=6.7 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propanediol (Preparation example 61) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.8 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=6.4 Hz, 3H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 7.04˜7.50 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-fluorophenyl)-(R,R)-1,2-propanediol (Preparation example 62) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.5 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.15 (d, J=6.4 Hz, 3H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 7.04˜7.50 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propanediol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.1 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.27 (d, J=6.4 Hz, 3H), 3.99 (t, J=6.0 Hz, 1H), 4.81 (d, J=4.0 Hz, 1H), 7.01˜7.87 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-iodophenyl)-(R,R)-1,2-propanediol (Preparation example 67) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (2.8 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.26 (d, J=6.4 Hz, 3H), 3.98 (t, J=6.2 Hz, 1H), 4.88 (d, J=4.4 Hz, 1H), 7.00˜7.87 (m, 4H)
The substantially same method as described in Preparation Example 69 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (3.3 g, yield 90˜120%).
1H NMR (400 MHz, CDCl3) δ−0.053 (s, 9H), 0.044 (s, 9H), 1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 7.01˜7.87 (m, 4H)
To a stirred solution of crude 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (preparation example 69, 104 g, 0.31 mol) in toluene (670 mL) was added by Chlorosulfonyl isocynate (62.5 mL, 0.71 mol) at 0° C. The reaction mixture was stirred for 2 hr. The reaction mixture was quenched with ice water and then was stirred by additional cold H2O (500 mL) for 2 hr. After separation of organic layer, the aqueous was adjusted pH2˜3 with sat. NaHCO3 (400 mL) and extracted with EtOAc (300 mL×3). The EtOAc layer was washed with sat. NaHCO3 (500 mL) and H2O (500 mL). The organic phase was treated with Charcol for 1.5 hr. The organic phase was filtered with Cellite, dried over MgSO4. Filterion and concentration under vacuum provided the title compound of white solid (yield 85% (71.1 g), ee=99.9% MP=83˜84° C., [α]D=+57.8 (c=0.25, MeOH))
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4, 3H), 2.91 (d, J=4.8, 1H), 4.68 (br s, 2H), 5.06˜5.09 (m, 1H), 5.18˜5.21 (m, 1H), 7.23˜7.39 (m, 3H), 7.55 (dd, J=1.6, J=7.8, 1H)
13C NMR (100 MHz, CDCl3) δ16.4, 73.1, 75.0, 127.0, 128.4, 129.1, 129.5, 132.7, 138.0, 156.6
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy) propane (Preparation example 70) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (5.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4, 3H), 2.91 (d, J=4.8, 1H), 4.68 (br s, 2H), 5.06˜5.09 (m, 1H), 5.18˜5.21 (m, 1H), 7.23˜7.39 (m, 3H), 7.55 (dd, J=1.6, J=7.8, 1H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 71) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (3.8 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4, 3H), 2.91 (d, J=4.8, 1H), 4.68 (br s, 2H), 5.06˜5.09 (m, 1H), 5.18˜5.21 (m, 1H), 7.23˜7.39 (m, 3H), 7.55 (dd, J=1.6, J=7.8, 1H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(S,R)-1,2-(Bis-trimethylsilanyloxy) propane (Preparation example 72) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.4 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4, 3H), 2.91 (d, J=4.8, 1H), 4.68 (br s, 2H), 5.06˜5.09 (m, 1H), 5.18˜5.21 (m, 1H), 7.23˜7.39 (m, 3H), 7.55 (dd, J=1.6, J=7.8, 1H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(R,S)-1,2-(Bis-trimethylsilanyloxy) propane (Preparation example 73) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.3 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4, 3H), 2.91 (d, J=4.8, 1H), 4.68 (br s, 2H), 5.06˜5.09 (m, 1H), 5.18˜5.21 (m, 1H), 7.23˜7.39 (m, 3H), 7.55 (dd, J=1.6, J=7.8, 1H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation example 74) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.6 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.96 (t, J=7.4 Hz, 3H), 1.57˜1.73 (m, 2H), 3.01 (d, J=5.6 Hz, 1H), 4.74 (br s, 2H), 4.95 (dt, J=7.2, 8.8 Hz, 1H), 5.23 (t, J=5.6 Hz, 1H), 7.22˜7.54 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 75) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.5 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ 0.94 (t, J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 2.92 (s, 1H), 4.78 (br s, 2H), 4.91˜4.96 (m, 1H), 5.22 (d, J=5.5 Hz, 1H), 7.20˜7.54 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 76) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.9 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ 0.97 (t, J=7 Hz, 3H), 1.58˜1.74 (m, 2H), 2.94 (d, J=6 Hz, 1H), 4.69 (br s, 2H), 4.94˜4.99 (m, 1H), 5.24 (t, J=6 Hz, 1H), 7.23˜7.56 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-3-methyl-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 77) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.01 (d, J=6.4 Hz, 3H), 1.09 (d, J=6.8 Hz, 3H), 2.06 (m, 1H), 2.75 (d, J=6.8 Hz, 1H), 4.58 (br s, 2H), 4.85˜4.88 (m, 1H), 5.34˜5.37 (m, 1H), 7.22˜7.33 (m, 2H), 7.35˜7.37 (m, 1H), 7.51˜7.53 (m, 1H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-3-methyl-(R,R)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 78) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.6 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.01 (d, J=6.8 Hz, 3H), 1.09 (d, J=6.8 Hz, 3H), 2.06 (m, 1H), 2.73 (d, J=6.8 Hz, 1H), 4.57 (br s, 2H), 4.85˜4.88 (m, 1H), 5.34˜5.37 (m, 1H), 7.24˜7.30 (m, 2H), 7.35˜7.37 (m, 1H), 7.51˜7.53 (m, 1H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-3-methyl-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 79) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (d, J=6.4 Hz, 3H), 1.09 (d, J=6.4 Hz, 3H), 2.08 (m, 1H), 2.76 (d, J=6.0 Hz, 1H), 4.59 (br s, 2H), 4.87 (dd, J=7.2 Hz, 4.4 Hz, 1H), 5.36 (t, J=4.6, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 80) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.3 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.88 (t, J=7 Hz, 3H), 1.33˜1.42 (m, 4H), 1.53˜1.71 (m, 2H), 2.89 (d, J=5.6 Hz, 1H) 4.64 (br s, 2H), 5.04 (dt, J=5.0, 9.0 Hz, 1H), 5.20 (t, J=5.6 Hz, 1H), 7.23˜7.55 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 81) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.2 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ 0.89 (dd, J=5 Hz, 3H), 1.28˜1.43 (m, 4H), 1.52˜1.58 (m, 1H), 1.65˜1.72 (m, 1H), 2.90 (d, J=6 Hz, 1H), 4.64 (br s, 2H), 5.01˜5.06 (m, 1H), 5.22 (t, J=6 Hz, 1H), 7.22˜7.56 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-chlorophenyl)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 82) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.1 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ 0.88 (dd, J=5 Hz, 3H), 1.31˜1.43 (m, 4H), 1.63˜1.70 (m, 1H), 1.52˜1.60 (m, 1H), 3.06 (d, J=6 Hz, 1H), 4.75 (br s, 2H), 5.00˜5.05 (m, 1H), 5.21 (t, J=6 Hz, 1H), 7.22˜7.55 (m, 4H)
1-(2-chlorophenyl)-(S,S)-1,2-propanediol (2.4 g) obtained in Preparation Example 14, tetrahydrofuran (THF, 12 ml), and carbonyldiimidazole (CDI, 3.12 g) were put into a flask and stirred at the room temperature. After approximately 3 hours, methylamine solution (CH3NH2, 4 ml (33% in EtOH)) was added thereto. When the reaction was completed, the obtained product was washed with 1M HCl solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound (1.6 g, yield 51%).
1H NMR (400 MHz, CDCl3) δ1.03˜1.25 (m, 3H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.20˜7.53 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that propylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (0.79 g, yield 25%).
1H NMR (400 MHz, CDCl3) δ0.90 (t, J=6.8 Hz, 3H), 1.20 (d, J=5.96 Hz, 3H), 1.49 (dd, J=14.2 Hz, 2H), 3.11 (d, J=6.28 Hz, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 7.22˜7.53 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that isopropylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.5 g, yield 41%).
1H NMR (400 MHz, CDCl3) δ1.14 (dd, J=6.5 Hz, 6H), 1.19 (d, J=6.4 Hz, 3H), 3.21 (s, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.20-7.53 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that cyclopropylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (2.2 g, yield 43%).
1H NMR (400 MHz, CDCl3) δ0.50-0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 1.25 (s, 3H), 2.56˜2.61 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that cyclohexylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.1 g, yield 26%).
1H NMR (400 MHz, CDCl3) δ1.06˜1.40 (m, 7H), 1.56˜1.61 (m, 2H), 1.69˜1.71 (m, 2H), 1.87˜1.94 (m, 2H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.20˜7.53 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that benzylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.2 g, yield 18%).
1H NMR (400 MHz, CDCl3) δ 1.27 (d, J=10 Hz, 3H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.15˜7.56 (m, 9H)
The substantially same method as described in Example 15 was conducted, except that 2-aminonorbornane was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.7 g, yield 32%).
1H NMR (400 MHz, CDCl3) δ0.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.22˜7.55 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-propanediol (Preparation example 15) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (3.36 g, yield 60%).
1H NMR (400 MHz, CDCl3) δ 1.20 (d, J=6.8 Hz, 3H), 2.80 (d, J=4.8 Hz, 3H), 3.20 (d, J=4.4 Hz, 1H), 4.75 (br s, 1H), 5.03˜5.09 (m, 1H), 5.14˜5.17 (m, 1H), 7.22˜7.55 (m, 4H)
The substantially same method as described in Example 22 was conducted, except that propylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (3.1 g, yield 53%).
1H NMR (400 MHz, CDCl3) δ0.92 (t, J=7.6 Hz, 3H), 1.21 (d, J=6.4 Hz, 3H), 1.51 (m, 2H), 3.09˜3.14 (m, 2H), 3.28 (d, J=4.4 Hz, 1H), 4.82 (br s, 1H), 5.03˜5.09 (m, 1H), 5.14˜5.17 (m, 1H), 7.22˜7.55 (m. 4H)
The substantially same method as described in Example 22 was conducted, except that isopropylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (0.16 g, yield 27%).
1H NMR (400 MHz, CDCl3) δ0.88˜1.16 (m, 6H), 1.19˜1.26 (m, 3H), 3.34 (s, 1H), 3.71˜3.78 (m, 1H), 4.62 (br s, 1H), 5.03 (t, J=5.8 Hz, 1H), 5.13 (d, J=4.9 Hz, 1H), 7.20˜7.53 (m, 4H)
The substantially same method as described in Example 22 was conducted, except that cyclopropylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (3.7 g, yield 60%).
1H NMR (400 MHz, CDCl3) δ0.49˜0.54 (m, 2H), 0.74 (d, J=7.2 Hz, 2H), 1.22 (s, 3H), 2.55˜2.60 (m, 1H), 3.16 (s, 1H), 5.00 (s, 1H), 5.04˜5.11 (m, 1H), 5.16 (s, 1H), 7.23˜7.54 (m, 4H)
The substantially same method as described in Example 22 was conducted, except that cyclohexylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.9 g, yield 28%).
1H NMR (400 MHz, CDCl3) δ1.05˜1.38 (m, 8H), 1.58˜1.70 (m, 3H), 1.85˜1.95 (m, 2H), 3.39˜3.47 (m, 1H), 3.56 (s, 1H), 4.79 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.2 Hz, 1H), 7.20˜7.54 (m, 4H)
The substantially same method as described in Example 22 was conducted, except that benzylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (0.52 g, yield 19%).
1H NMR (400 MHz, CDCl3) δ1.25 (d, J=6 Hz, 3H), 1.64 (s, 1H), 3.13 (d, J=4.4 Hz, 1H), 4.37 (d, J=5.6 Hz, 2H), 5.12˜5.19 (m, 2H), 7.23˜7.55 (m, 9H)
The substantially same method as described in Example 22 was conducted, except that 2-aminonorbornane was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.7 g, yield 20˜50%).
1H NMR (400 MHz, CDCl3) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.22˜7.55 (m, 4H)
The substantially same method as described in Example 15 was conducted, except that 1-(2-chlorophenyl)-1,2-propanediol (Preparation example 16) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (2.6 g, yield 45%).
1H NMR (400 MHz, CDCl3) δ 1.21 (d, J=6 Hz, 3H), 2.81 (d, J=5 Hz, 3H), 3.14 (d, J=4 Hz, 1H), 4.72 (br s, 1H), 5.07 (dd, J=6 Hz, 1H), 5.16 (t, J=6 Hz, 1H), 7.22˜7.56 (m, 4H)
The substantially same method as described in Example 29 was conducted, except that propylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.0 g, yield 17%).
1H NMR (400 MHz, CDCl3) δ 0.92 (t, J=7 Hz, 3H), 1.21 (d, J=6 Hz, 3H), 1.53 (dd, J=7 Hz, 2H), 3.13 (dd, J=7 Hz, 2H), 3.28 (d, 1H), 4.82 (S, 1H), 5.06 (dd, J=7 Hz, 1H), 5.16 (t, J=5 Hz, 1H), 7.21˜7.56 (m, 4H)
The substantially same method as described in Example 29 was conducted, except that isopropylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (0.54 g, yield 16%).
1H NMR (400 MHz, CDCl3) δ 1.16 (dd, J=6 Hz, 6H), 1.21 (d, J=6 Hz, 3H), 3.23 (d, J=6 Hz, 1H), 3.75˜3.84 (m, 1H), 4.61 (br s, 1H), 5.06 (t, J=6 Hz, 1H), 5.16 (t, J=6 Hz, 1H), 7.22˜7.56 (m, 4H)
The substantially same method as described in Example 29 was conducted, except that cyclopropylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.0 g, yield 17%).
1H NMR (400 MHz, CDCl3) δ 0.50 (t, J=6 Hz, 2H), 0.77 (t, J=3 Hz, 2H), 1.12 (d, J=7 Hz, 3H), 2.53˜2.59 (m, 1H), 3.22 (d, J=4 Hz, 1H), 5.08 (dd, J=6 Hz, 1H), 5.15 (S, 1H), 7.22˜7.55 (m, 4H)
The substantially same method as described in Example 29 was conducted, except that cyclohexylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (2.2 g, yield 33%).
1H NMR (400 MHz, CDCl3) δ 1.07˜1.17 (m, 3H), 1.21 (d, J=6 Hz, 3H), 1.29˜1.42 (m, 3H), 1.72 (dd, J=6 Hz, 2H), 1.92 (dd, J=6 Hz, 2H), 3.26 (d, J=4 Hz, 1H), 3.46 (t, J=4 Hz, 1H), 4.68 (d, J=6 Hz, 1H), 5.07 (dd, J=6 Hz, 1H), 5.16 (t, J=6 Hz, 1H), 7.22˜7.55 (m, 4H)
The substantially same method as described in Example 29 was conducted, except that benzylamine was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.3 g, yield 19%).
1H NMR (400 MHz, CDCl3) δ 1.25 (d, J=6 Hz, 3H), 3.16 (d, J=4 Hz, 1H), 4.36 (d, J=6 Hz, 2H), 5.14 (dd, J=6 Hz, 3H), 7.23˜7.56 (m, 9H), yield: 19% (1.3 g)
The substantially same method as described in Example 29 was conducted, except that 2-aminonorbornane was used instead of methylamine solution (CH3NH2 in EtOH), to obtain the title compound (1.7 g, yield 20˜50%).
1H NMR (400 MHz, CDCl3) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.22˜7.55 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 83) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.8 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.22 (d, J=6.4 Hz, 3H), 4.16 (br t, 1H) 4.96 (br t, 3H), 5.07 (t, J=4.8 Hz, 1H), 7.23˜7.52 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 84) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.6 g, yield 60˜90%)
The substantially same method as described in Example 1 was conducted, except that 1-(2,3-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 85) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.4 g, yield 60˜90%)
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 86) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.3 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.96 (t, J=7.4 Hz, 3H), 1.58˜1.74 (m, 2H), 2.98 (d, J=5.6 Hz, 1H) 4.68 (br s, 2H), 5.59 (dt, J=5.2, 8.8 Hz, 1H), 5.19 (t, J=5.4 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 87) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.92 (t, J=7.4 Hz, 3H), 1.30˜1.38 (m, 1H), 1.57˜1.64 (m, 1H), 3.74 (d, J=9.2 Hz, 1H), 4.80 (br s, 2H), 5.40˜5.50 (m, 2H), 7.17˜7.34 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 88) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.9 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (1, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 89) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.4 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (1, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.16˜7.33 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 90) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.2 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.89 (t, J=3.6 Hz, 3H), 1.28˜1.42 (m, 4H), 1.52˜1.59 (m, 1H), 1.64˜1.71 (m, 1H), 2.98 (d, J=5.6 Hz, 1H), 4.67 (br s, 2H), 4.96˜5.00 (m, 1H), 5.17 (t, J=5.6 Hz, 1H), 7.30˜7.49 (m 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 91) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.1 g, yield 60˜90%)
1H NMR (400 MHz, CDCl3) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 92) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.2 g, yield 60˜90%),
1H NMR (400 MHz, CDCl3) δ1.22 (d, J=6.4 Hz, 3H), 4.16 (br t, 1H) 4.96 (br t, 3H), 5.07 (t, J=4.8 Hz, 1H), 7.23˜7.52 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 93) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%),
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 1 was conducted, except that 1-(2,3-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 94) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.0 g, yield 60˜90%)
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 95) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.3 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.96 (t, J=7.4 Hz, 3H), 1.58˜1.74 (m, 2H), 2.98 (d, J=5.6 Hz, 1H) 4.68 (br s, 2H), 5.59 (dt, J=5.2, 8.8 Hz, 1H), 5.19 (t, J=5.4 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 96) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.5 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.92 (t, J=7.4 Hz, 3H), 1.30˜1.38 (m, 1H), 1.57˜1.64 (m, 1H), 3.74 (d, J=9.2 Hz, 1H), 4.80 (br s, 2H), 5.40˜5.50 (m, 2H), 7.17˜7.34 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(R,R)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 97) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.8 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (1, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(R,R)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 98) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.6 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (1, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.16˜7.33 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 99) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.5 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.89 (t, J=3.6 Hz, 3H), 1.28˜1.42 (m, 4H), 1.52˜1.59 (m, 1H), 1.64˜1.71 (m, 1H), 2.98 (d, J=5.6 Hz, 1H), 4.67 (br s, 2H), 4.96˜5.00 (m, 1H), 5.17 (t, J=5.6 Hz, 1H), 7.30˜7.49 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 100) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.4 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 101) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.22 (d, J=6.4 Hz, 3H), 4.16 (br t, 1H) 4.96 (br t, 3H), 5.07 (t, J=4.8 Hz, 1H), 7.23˜7.52 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 102) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.4 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 1 was conducted, except that 1-(2,3-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 103) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.6 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 104) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.96 (t, J=7.4 Hz, 3H), 1.58˜1.74 (m, 2H), 2.98 (d, J=5.6 Hz, 1H) 4.68 (br s, 2H), 5.59 (dt, J=5.2, 8.8 Hz, 1H), 5.19 (t, J=5.4 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 105) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.4 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.92 (t, J=7.4 Hz, 3H), 1.30˜1.38 (m, 1H), 1.57˜1.64 (m, 1H), 3.74 (d, J=9.2 Hz, 1H), 4.80 (br s, 2H), 5.40˜5.50 (m, 2H), 7.17˜7.34 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 106) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.9 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 107) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.16˜7.33 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 108) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.6 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.89 (t, J=3.6 Hz, 3H), 1.28˜1.42 (m, 4H), 1.52˜1.59 (m, 1H), 1.64˜1.71 (m, 1H), 2.98 (d, J=5.6 Hz, 1H), 4.67 (br s, 2H), 4.96˜5.00 (m, 1H), 5.17 (t, J=5.6 Hz, 1H), 7.30˜7.49 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-(Bis-trimethylsilanyloxy)hexane (Preparation Example 109) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.5 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.17˜7.35 (m, 3H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 110) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.8 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.19 (d, J=5.2 Hz, 3H), 2.93 (d, J=4.4 Hz, 1H), 4.71 (br s, 2H), 4.99˜5.06 (m, H), 7.04˜7.48 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-fluorophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 111) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.6 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.19 (d, J=5.2 Hz, 3H), 2.93 (d, J=4.4 Hz, 1H), 4.71 (br s, 2H), 4.99˜5.06 (m, H), 7.04˜7.48 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 112) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.2 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 7.00˜7.76 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-iodophenyl)-(R,R)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation Example 113) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (1.7 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.27 (d, J=6.4 Hz, 3H), 2.95 (d, J=3.6 Hz, 1H), 4.73 (br s, 2H), 5.01˜5.11 (m, 2H), 7.01˜7.86 (m, 4H)
The substantially same method as described in Example 1 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)butane (Preparation Example 114) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-(Bis-trimethylsilanyloxy)propane (Preparation example 69) to obtain the title compound (2.1 g, yield 60˜90%).
1H NMR (400 MHz, CDCl3) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 7.00˜7.76 (m, 4H)
1-(2-chlorophenyl)-(S,S)-1,2-propanediol (2.33 g, Preparation example 14) obtained in Preparation Example 14, tetrahydrofuran (THF, 12 ml), and carbonyldiimidazole (CDI, 3.04 g) were put into a flask and stirred at the room temperature. After approximately 3 hours, ammonia solution (NH4OH, 4 ml) was added thereto. When the reaction was completed, the obtained product was washed with 1M HCl solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgSO4), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound (0.28 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.8 Hz, 3H), 2.13 (d, J=4.4 Hz, 1H), 4.12˜4.16 (m, 1H), 4.85 (br s, 2H), 5.98 (d, J=5.6 Hz, 1H), 7.24˜7.43 (m, 4H)
The substantially same method as described in Example 68 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-propanediol (Preparation Example 15) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (0.77 g, yield 16%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4 Hz, 3H), 2.04 (d, J=4.8 Hz, 1H), 4.11˜4.18 (m, 1H), 4.74 (br s, 2H), 6.00 (d, J=5.6 Hz, 1H), 7.24˜7.43 (m, 4H)
The substantially same method as described in Example 68 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-propanediol (Preparation Example 16) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14) to obtain the title compound (0.16 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.24 (d, J=6.4 Hz, 3H), 2.04 (d, J=4.8 Hz, 1H), 4.11˜4.18 (m, 1H), 4.74 (br s, 2H), 6.00 (d, J=5.6 Hz, 1H), 7.24˜7.43 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 15, to obtain the title compound (0.70 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.21 (d, J=6.4 Hz, 3H), 2.80 (d, J=4.8 Hz, 3H), 3.12 (s, 1H), 4.09˜4.16 (m, 1H), 4.86 (br s, 1H), 5.99 (d, J=6.0 Hz, 1H), 7.23˜7.40 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 22, to obtain the title compound (0.69 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.21 (d, J=6.4 Hz, 3H), 2.80 (d, J=4.8 Hz, 3H), 3.12 (s, 1H), 4.09˜4.16 (m, 1H), 4.86 (br s, 1H), 5.99 (d, J=6.0 Hz, 1H), 7.23˜7.40 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 29, to obtain the title compound (0.73 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 1.22 (d, J=6 Hz, 3H), 2.15 (d, J=4 Hz, 1H), 2.81 (d, J=5 Hz, 3H), 4.12 (dd, J=6 Hz, 1H), 4.83 (br s, 1H), 6.00 (d, J=6 Hz, 1H), 7.23˜7.41 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 16, to obtain the title compound (0.15 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 0.91 (t, J=7 Hz, 3H), 1.22 (d, J=6 Hz, 3H), 1.52 (dd, J=7 Hz, 2H), 2.23 (d, J=4 Hz, 1H), 3.09˜3.21 (m, 2H), 4.09˜4.17 (m, 1H), 4.93 (s, 1H), 5.99 (d, J=6 Hz, 1H), 7.23˜7.47 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 23, to obtain the title compound (0.04 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 0.91 (t, J=7 Hz, 3H), 1.22 (d, J=6 Hz, 3H), 1.52 (dd, J=7 Hz, 2H), 2.23 (d, J=4 Hz, 1H), 3.09˜3.21 (m, 2H), 4.09˜4.17 (m, 1H), 4.93 (s, 1H), 5.99 (d, J=6 Hz, 1H), 7.23˜7.47 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 30, to obtain the title compound (0.15 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 0.91 (t, J=7 Hz, 3H), 1.22 (d, J=6 Hz, 3H), 1.52 (dd, J=7 Hz, 2H), 2.23 (d, J=4 Hz, 1H), 3.09˜3.21 (m, 2H), 4.09˜4.17 (m, 1H), 4.93 (s, 1H), 5.99 (d, J=6 Hz, 1H), 7.23˜7.47 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 17, to obtain the title compound (0.42 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.10 (d, J=6.0 Hz, 3H), 1.15˜1.19 (m, 6H), 2.41 (s, 1H), 3.76˜4.08 (m, 1H), 4.34 (s, 1H), 4.83 (br s 1H), 5.95 (d, J=5.3 Hz, 1H), 7.19˜7.39 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 24, to obtain the title compound (0.5 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6 Hz, 3H), 1.20 (dd, J=9.2 Hz, 6H), 2.23 (s, 1H), 3.77˜3.82 (m, 1H), 4.10 (s, 1H), 4.76 (br s, 1H), 5.98 (d, J=5.6 Hz, 1H), 7.23˜7.41 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 31, to obtain the title compound (0.09 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 1.14 (d, J=6 Hz, 3H), 1.21 (dd, J=6 Hz, 6H), 2.16 (d, J=5 Hz, 1H), 3.81 (t, J=6 Hz, 1H), 4.11 (d, J=5 Hz, 1H), 4.73 (br s, 1H), 5.98 (d, J=5 Hz, 1H), 7.24˜741 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 18, to obtain the title compound (0.53 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.53˜0.60 (m, 2H), 0.74 (s, 2H), 1.21 (d, J=6.0 Hz, 3H), 2.19 (s, 1H), 2.59 (s, 1H), 4.11˜4.15 (m, 1H), 5.13 (br s, 1H), 5.99 (d, J=5.20 Hz, 1H), 7.23˜7.40 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 25, to obtain the title compound (0.58 g, yield 10%).
1H NMR (400 MHz, CDCl3) δ0.53˜0.60 (m, 2H), 0.74 (s, 2H), 1.21 (d, J=6.0 Hz, 3H), 2.19 (s, 1H), 2.59 (s, 1H), 4.11˜4.15 (m, 1H), 5.13 (br s, 1H), 5.99 (d, J=5.20 Hz, 1H), 7.23˜7.40 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 32, to obtain the title compound (0.38 g, yield 14%).
1H NMR (400 MHz, CDCl3) δ 0.71 (s, 2H), 1.19 (d, J=6 Hz, 3H), 2.45 (S, 1H), 2.57 (S, 1H), 4.08˜4.12 (m, 1H), 5.26 (s, 1H), 5.97 (d, J=4 Hz, 1H), 7.22˜7.54 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 19, to obtain the title compound (0.24 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.10˜1.39 (m, 7H), 1.61 (s, 3H), 1.71˜1.74 (m, 2H), 1.87 (d, J=11.2 Hz, 1H), 2.48 (d, J=10.8 Hz, 1H), 3.46 (t, J=4 Hz, 1H), 4.10˜4.11 (m, 1H), 4.80 (br s 1H), 5.97 (d, J=5.6 Hz, 1H), 7.23˜7.41 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 26, to obtain the title compound (0.35 g, yield 10%).
1H NMR (400 MHz, CDCl3) δ1.10˜1.39 (m, 7H), 1.61 (s, 3H), 1.71˜1.74 (m, 2H), 1.87 (d, J=11.2 Hz, 1H), 2.48 (d, J=10.8 Hz, 1H), 3.46 (t, J=4 Hz, 1H), 4.10˜4.11 (m, 1H), 4.80 (br s 1H), 5.97 (d, J=5.6 Hz, 1H), 7.23˜7.41 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 33, to obtain the title compound (0.26 g, yield 10%).
1H NMR (400 MHz, CDCl3) δ 1.12˜1.19 (m, 3H), 1.22 (d, J=6 Hz, 3H), 1.27˜1.37 (m, 1H), 1.71 (t, J=6 Hz, 2H), 1.86˜1.88 (m, 1H), 1.97˜2.00 (m, 1H), 2.18 (d, J=4 Hz, 1H), 3.47 (S, 1H), 4.12 (t, J=6 Hz, 1H), 4.78 (S, 1H), 5.97 (d, J=6 Hz, 1H), 7.23˜7.40 (m, 4H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 20, to obtain the title compound (0.19 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 1.23 (d, J=6 Hz, 3H), 2.16 (d, J=4 Hz, 1H), 4.12 (t, J=6 Hz, 1H), 4.31˜4.44 (m, 2H), 5.22 (br S, 1H), 6.04 (d, J=6 Hz, 1H), 7.27˜7.42 (m, 9H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 27, to obtain the title compound (0.07 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ 1.23 (d, J=6 Hz, 3H), 2.16 (d, J=4 Hz, 1H), 4.12 (t, J=6 Hz, 1H), 4.31˜4.44 (m, 2H), 5.22 (br S, 1H), 6.04 (d, J=6 Hz, 1H), 7.27˜7.42 (m, 9H)
A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 34, to obtain the title compound (0.21 g, yield 14%).
1H NMR (400 MHz, CDCl3) δ 1.23 (d, J=6 Hz, 3H), 2.16 (d, J=4 Hz, 1H), 4.12 (t, J=6 Hz, 1H), 4.31˜4.44 (m, 2H), 5.22 (br S, 1H), 6.04 (d, J=6 Hz, 1H), 7.27˜7.42 (m, 9H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-propanediol (Preparation example 26) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.05 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.39 (d, J=2.0 Hz, 2H), 7.50 (dd, J=8.4 Hz, 2.0 Hz, 1H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-propanediol (Preparation example 38) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.07 g, yield 24%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,3-dichlorophenyl)-(S,S)-1,2-propanediol (Preparation example 57) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.08 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-butanediol (Preparation example 29) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.07 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-butanediol (Preparation example 41) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.11 g, yield 29%).
1H NMR (400 MHz, CDCl3) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 32) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.01 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 44) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.03 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-hexanediol (Preparation example 35) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.21 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-hexanediol (Preparation example 47) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.06 g, yield 29%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.16˜7.34 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-propanediol (Preparation example 27) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.04 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-propanediol (Preparation example 39) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.09 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,3-dichlorophenyl)-(R,R)-1,2-propanediol (Preparation example 58) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.25 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-butanediol (Preparation example 30) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.08 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-butanediol (Preparation example 42) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.09 g, yield 10˜30%). 1H NMR (400 MHz, CDCl3) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(R,R)-1,2-propanediol (Preparation example 33) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.01 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(R,R)-1,2-propanediol (Preparation example 45) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.01 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.00 (1, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-hexanediol (Preparation example 36) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.21 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-hexanediol (Preparation example 48) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.12 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.16˜7.34 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-propanediol (Preparation example 28) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.05 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-propanediol (Preparation example 40) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.06 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,3-dichlorophenyl)-1,2-propanediol (Preparation example 59) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.02 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-butanediol (Preparation example 31) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.07 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-butanediol (Preparation example 43) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.10 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-1,2-propanediol (Preparation example 34) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.04 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-1,2-propanediol (Preparation example 46) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.01 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.25˜7.40 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-hexanediol (Preparation example 37) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.21 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.30˜7.50 (m, 3H)
The substantially same method as described in Example 68 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-hexanediol (Preparation example 49) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol (Preparation example 14), to obtain the title compound (0.12 g, yield 10˜30%).
1H NMR (400 MHz, CDCl3) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.16˜7.34 (m, 3H)
Compounds 1 to 115 produced in Examples 1 to 115 were summarized in following Tables 1 and 2.
1.1. Animals
For testing, male mice (ICR) were purchased from ORIENT BIO INC. (Korea), divided into several groups with 6 mice in each group, and were adapted for 4-5 days. The mice having the weight ranging from 19 g to 26 g were employed for the test. The pharmacological effect of the test compounds on muscle relaxation was evaluated by Rotarod test, grip strength test, and muscular force (wire hang) test. All mice were adapted to the test environment at one hour before starting the tests. The pharmacological effects of all the test compounds were evaluated by administration through peritoneal cavity of the mice (10 ul/g, bw).
1.2. Measurement of Muscle Relaxation Activity by Endurance Time on a Rotarod Rotating at Accelerated Speed
At 24 hours before testing, the mice to be tested were preliminarily trained for 5 minutes on a rod rotating at the rate of 6 revolutions per a minute. The pharmacological effect on muscle relaxation of the test compounds were evaluated by observing the mice on a rod for 5 minutes, where the rod was accelerated from 4 to 40 revolutions per a minute during the test time. The endurance time that each mouse endures on the acceleratedly rotated rod without falling off from the rod was recorded. As test time for evaluation, a maximum of 5 minutes was applied. In case the mouse does not fall off from the rod for testing time, the endurance time was recorded as 5 minutes. All the test compounds were intraperitoneally administered (10 ul/g, bw) to the mice at 15 minutes, 30 minutes, 1 hour, and 2 hours prior to the testing, and the median effective concentration (ED50) was determined at the time that the drug exhibits its maximum pharmacological effect. The obtained results were shown in following Table 1. This experimentation was conducted according to the method described in the reference, ‘Monville et al. (2006) Comparison of incremental and accelerating protocol of the rotarod test for the assessment of motor deficits in the 6-OHDA model. J. Neurosci. Meth. 158: 219-223’.
1.3. Measurement of Muscle Relaxation Activity by Residence Time on a Rotarod Rotating at a Fixed Speed
All the mice to be tested were preliminarily trained for 5 minutes on a rod rotating at the rate of 15 revolutions per a minute. The mice that could not remain on the rod without falling off therefrom for a minimum of 2 minutes were excluded from this testing. After the training, all the mice were allowed to rest for 45-60 minutes. Before the administration of the test compounds, the mice were subjected to a further training for one minute on the rod rotating under the same condition, where the mice falling off from the rod were excluded from this experimentation. All the test compounds were intraperitoneally administered (10 ul/g, bw) to the mice at 15 minutes, 30 minutes, 1 hour, and 2 hours prior to the testing, and the median effective concentration (ED50) was determined at the time (generally 15 min, 30 min or 60 min) that the compounds exhibit their maximum pharmacological effect. In case a mouse stays on the rod until the test is finished, the time was recorded as 10 minutes. As test time for evaluation, a maximum of 10 minutes was applied. The obtained results were shown in following Table 3. This experimentation was conducted according to the method described in the reference, ‘Yasuda et al. (2005) Antipyretic, analgesic and muscle relaxant activities of Pueraria isoflavonoids and their metabolites from Pueraria lobata Ohwi—a traditional Chinese drug. Biol. Pharm. Bull. 28: 1224-1228’.
1.4. Measurement of Muscle Relaxation Activity by Grip Strength
A grip strength test using the test animals' forelimbs was performed using an instrument equipped with triangle ring and designed so as to easily grip with the forelimbs of experimental animals, manufactured from Ugo Basile Inc. (Ugo Basile, Mode147106, Italy). The test was conducted before and after administration of the compounds to evaluate the effects thereof. All the test compounds were intraperitoneally administered (10 ul/g, bw) at 15 minutes, 30 minutes, 1 hour, and 2 hours before test, and the median effective concentration (ED50) was determined at the time (generally 15 min, 30 min or 60 min) that the compounds exhibits their maximum pharmacological effect. The mouse was made to grip the rod with its forelimbs, and its tail was pulled, where the force at which the mouse detached from the rod was recorded. The instrument indicated the force in grams. All of the mice were given 3 opportunities for test, and the 3 highest values among the test opportunities were selected and the mean value was used as the test result. The obtained results are shown in Table 3. This experimentation was conducted according to the method described in the reference, ‘Nevins et al. (1993) Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice. Psychopharmacol. 110: 92-96’.
1.5. Measurement of Muscle Relaxation Activity by Wire Hang
This experimentation was conducted using a metal wire of 30 cm in length, which was suspended between two pillars at a height of about 40 cm from the bottom covered with a soft pad. All the test compounds were administered to the mice through peritoneal cavity (10 ul/g, bw) at 15 minutes, 30 minutes, 1 hour, and 2 hours prior to the testing, and the median effective concentration (ED50) was determined at the time that the compound exhibits the maximum pharmacological effect. Each mouse was made to grip the wire using two forelimbs, and the elapse time before the mouse fell off from the wire to the pad on the bottom was recorded in seconds. Each mouse was given 5 opportunities for this test at an interval of 2 minutes period. The highest 3 records among the test opportunities were selected and the mean value was used as the test result. The obtained results are shown in Table 3. This experimentation was conducted according to the method described in the reference, ‘Jacqueline N. Crawley (1999) Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 835: 18-26’.
[Statistical Analysis]
The obtained results are shown as mean±sem. The difference between the groups was statistically analyzed by ANOVA, and then, further examined by Dunnett's test or Bonferroni test. If p is less than 0.05, it was determined that the difference between the groups had statistical significance.
[Results]
The results of muscle relaxation activity of the phenyl carbamate compounds measured in above Experimental Examples 1.2 to 1.4 are shown in following Table 3. In the Table 3, the ED50 was represented by the concentration where the compound shows the 50% of muscle relaxation activity compared to the vehicle only (100%).
a = the concentration administered and effect (%) compared to that of control treated with vehicle only
2.1. Animals
All animal experiments were be carried out according to the National Institute of Health (NIH) guidelines for the care and use of laboratory animals, and approved by the State Provincial Office of Southern Finland. Altogether 80 male and female mice expressing mutated human SOD1-G93A transgene (heterozygous TgN-SOD1-G93A-1Gur; Gurney et al. (1994), Science 264, 1772. 1775) and 15 of their wild type littermates were used for the experiments. Animals were housed at a standard temperature (22±2° C.) and in a light controlled environment (lights on from 7 AM to 8 PM) with libitum access to food and water. PCR was used to genotype the mice before the start of the experiments.
The animals were grouped as follows:
To the animals, various experiments such as measurements of body weight, clinical score, and survival ratio, and open field test were conducted as follows, staring at 60 days of age until end-point (150 days of age).
2.2. Husbandry
All the provided mice were housed in groups of up to max 5 per cage (single sex, males), in a temperature (22±2° C.) and humidity (30-70%) controlled environment with a normal light-dark cycle (lights on from 7 AM to 8 PM). All mice were housed in cages with woodchip bedding covering the ground that is changed as frequently as needed to provide the animals with dry bedding. This basic environment was enriched with igloo (amber color, certified, transparent, BioServ). Food (Standard Lab Diet) and water were available ad libitum to the mice in their cages. Starting at age of 100 days or when the mouse reaches score 3 (referring to the following Example 2.8) whichever comes first, the transgenic G93A SOD1 mice received wet powdered food (Standard Lab Diet mixed with water to form a paste) placed inside a cup on the floor of the cages. In addition, water spouts were long enough to allow mice to easily access from floor level.
2.3. Breeding and Weaning
Eighty transgenic G93A SOD1 mice and 15 WT littermates were bred by Charles River Germany (under Cerebricon license) by mating hemizygous TG males (strain 002726M; B6SJL TG SOD1×G93A 1GUR/J, JAX) with WT females (strain 10012, JAX). Pups were weaned from their mothers and segregated to new cages for male, not exceeding 4-5 mice per cage. Tail/ear snips were taken during the weaned process at 3 weeks for genotype as described below.
2.4. Genotyping
The mice were ear-marked at the age of 3 weeks and ear/tail samples were collected at the same time for genotyping with PCR. Genotypes were determined by standard PCR by Charles River under the following conditions.
2.5. Experimental Set Up of Mice
For systematic drug testing, the following best practices were applied:
In setting up groups for testing (i.e., vehicle or drug treated), transgenic mice were randomized based on body weight just before beginning of treatment and also into groups so that whole litters of mice do not end up in a single testing group, to avoid ‘litter effect’ on the overall results.
Mice were housed in groups of 4-5 (max 5) mice, in case of aggressive behavior occurs, single housing was applied.
Experimentation was conducted in a blinded manner. For instance, the experimenter, dosing mice with the vehicle or the drug was different from the experimenter actually running the phenotype tests. Alternatively, if the same experimenter does dosing and phenotypic testing, that the experimenter does not have the code for mice receiving drug or vehicle and the vials with vehicle or drug were labeled so as not to allow distinction.
2.6. Drug Administration
Treatment with drug (Compound 1) was started at the age of 60 days and continued until the mice reached 150 days of age. The drug was administered p.o. once a day between 8-12 am. The drug solubilized in 30% (w/v) polyethyleneclycol 400 (PEG400), and the obtained solution was briefly vortexed and sonicated at RT (room temperature) for 20 minutes. Treatment solution of the drug was prepared fresh every day.
2.7. Measurement of Body Weight and Mortality
Since weight loss has proven to correlate well with disease development and is easily scored co-jointly with disease stage, the mice were weighted once-a-week at the age of 60 days to 90 days and three times a week after they reach the age of 91 days (13 weeks).
Mice were monitored twice-a-day by laboratory personnel (8 am to 4 pm) for “survival”. It is most optimal to measure “true survival” when mouse has no detectable heartbeat, which is prevented by IACUC (Institutional Animal Care and Use Committees) restrictions, and thus the “survival” end-point was defined as a 25% or more loss in body weight. For these alternative measures combining these “survival” data (body weight or temperature decrease) with survival of spontaneous death mice (age hound dead in a cage) is suitable. No tissues were collected from the terminated or spontaneously dead mice.
The measured rate (%) of survivor for each group was shown in
In addition, the average of the measured body weight for each group was shown in
2.8. Clinical Scoring
In the transgenic G93A SOD1 mice, early onset of the disease (ALS) (˜100 days) and rapid decline with the affected mice reaching the end stage on average within 40 days (typical survival of 130 to 160 days), has been reported.
The mice were carefully examined once a week until age of 90 days and two times a week after they reached the age of 91 days.
The earliest clinical signs were tremor and shaking of their limbs when the mice are suspended briefly in the air by their tails. The clinical scoring system is on a scale of 1 to 5; with 1 as the end-point for euthanasia and 5 as healthy with little or no signs of onset of disease. Animals were scored by lifting them gently by the base of their tails and observing them for tremors, stiffness and their ability to extend their limbs.
A more specific breakdown of the scoring system is as follows:
Onset of disease for each mouse was recorded when they reach a disease stage 4.
The measured clinical scores were shown in
2.9. Open Field Test
Open field test measurements were performed before the dosing is stated (baseline) and around day 90 (13th age week) and day 110 (16th age week). Mice born within 2-4 days were pooled for open field testing. Activity chambers (Med Associates Inc., St. Albans, Vt.; 27×27×10.3 cm) were equipped with IR (Infrared Ray) beams. Mice were placed in the center of the chamber and their behaviors were recorded for 10 minutes. The following parameters were recorded: distance moved.
The obtained results were shown in
2.10. Statistical Analysis
All values were presented as mean±standard deviation (SD) or Standard Error of Mean (SEM), and differences were considered to be statistically significant at the P<0.05 level. Statistical analyses were performed using StatsDirect statistical software. Differences between group means were compared with one-way ANOVA followed by Dunnet's post hoc test and within-group differences were assessed by two-way ANOVA followed by Dunnet's post hoc test (comparison to baseline=day 60). Kaplan-Meyer survival curves were provided for disease stage score and onset and for survival. Non-parametric data were analyzed with Kruskal-Wallis ANOVA (between groups) or Friedman ANIVA (within groups).
In the MES test (Ref., G. Villetti et al. Neuropharmacology 40 (2001) 866-878), an electrical stimulus (mice; 50 mA, 60 Hz, 0.2 sec and rats; 150 mA 60 Hz, 0.2 sec in the test animal) supplied by 11A Shocker (IITC Life Science Company) was delivered through corneal electrodes. All mice or rats assigned to any electroshock at peak time were treated with each test compound sample which was dissolved in 30% PEG400 prepared by saline solvent applied to oral before the test. If the test animal stretching their hind limb in a straight line weren't observed in the MES test, the results indicate that the test sample had an anti-epilepsy activity. Three doses of the test sample were administered orally to over 18 mice (6 mice per dose) for evaluating the respective doses at which 50% of the animals are protected from seizure (ED50). The value of ED50 (median effective dose) is calculated by Litchfield and Wicoxon log-probit method which is a dose-response relationship. Then, the test results are shown in following Table 4. Experimental animal, male ICR mice and male SD rats, were purchased from OrientBio or Nara biotech, Korea, and housed 4-5 mice per a cage for 4-5 days. The range of mice body weight was used between 19 and 26 grams and range of rats body weight was used between 100 and 130 grams.
The obtained results are shown as mean±sem. The difference between the groups was statistically analyzed by ANOVA, and then, further examined by Dunnett's test or Bonferroni test. If p is less than 0.05, it was determined that the difference between the groups had statistical significance.
The ED50 values according to time were measured in the test animals (mice and rats) after oral administration of test compound 1 as described in Biological Experimental Example I. The obtained results are shown in following Table 5 and
As shown in Table 5 and
This application claims priority to and the benefit of U.S. Provisional Application No. 61/580,409 filed in the United States Patent and Trademark Office on Dec. 27, 2011, the entire contents of which are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61580409 | Dec 2011 | US |
